139 related articles for article (PubMed ID: 26126567)
1. Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone.
Anforth R; Carlos G; Eiris N; Clements A; Fernandez-Peñas P
Med J Aust; 2015 Jul; 203(1):41-2. PubMed ID: 26126567
[No Abstract] [Full Text] [Related]
2. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
Degen A; Völker B; Kapp A; Gutzmer R
Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
[No Abstract] [Full Text] [Related]
3. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease.
Brugière C; Stefan A; Morice C; Cornet E; Moreau A; Allouche S; Verneuil L
Br J Dermatol; 2014 Dec; 171(6):1529-32. PubMed ID: 25066094
[TBL] [Abstract][Full Text] [Related]
4. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
[No Abstract] [Full Text] [Related]
5. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
[No Abstract] [Full Text] [Related]
6. Vemurafenib: an unusual UVA-induced photosensitivity.
Gelot P; Dutartre H; Khammari A; Boisrobert A; Schmitt C; Deybach JC; Nguyen JM; Seité S; Dréno B
Exp Dermatol; 2013 Apr; 22(4):297-8. PubMed ID: 23528218
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
Mangold AR; Bryce A; Sekulic A
J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
[No Abstract] [Full Text] [Related]
9. Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis?
Reigneau M; Granel-Brocard F; Geoffrois L; Bauman AS; Tréchot P; Barbaud A; Schmutz JL
Eur J Dermatol; 2013; 23(4):544-5. PubMed ID: 24001519
[No Abstract] [Full Text] [Related]
10. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib-induced pityriasis amiantacea: a case report.
Bilgiç Ö
Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
[TBL] [Abstract][Full Text] [Related]
12. A case of occipital neuralgia in a vemurafenib-treated melanoma patient.
Hoashi T; Matsumoto N; Serizawa N; Kataoka K; Nako T; Shirakawa N; Matano Y; Funasaka Y; Saeki H
Int J Dermatol; 2017 Jan; 56(1):e10-e11. PubMed ID: 27653311
[No Abstract] [Full Text] [Related]
13. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib (Zelboraf) with longer follow-up. Metastatic melanoma: a few extra months of life, but many adverse effects.
Prescrire Int; 2015 Apr; 24(159):89-90. PubMed ID: 25941696
[TBL] [Abstract][Full Text] [Related]
15. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib-induced granuloma annulare.
Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of vemurafenib in end stage renal failure.
Iddawela M; Crook S; George L; Lakkaraju A; Nanayakkara N; Hunt R; Adam WR
BMC Cancer; 2013 Dec; 13():581. PubMed ID: 24314265
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
19. The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing.
Woods JA; Ferguson JS; Kalra S; Degabriele A; Gardner J; Logan P; Ferguson J
J Photochem Photobiol B; 2015 Oct; 151():233-8. PubMed ID: 26318280
[TBL] [Abstract][Full Text] [Related]
20. Uveitic macular oedema after treatment with vemurafenib.
Fonollosa A; Mesquida M; Adan A
Acta Ophthalmol; 2015 Dec; 93(8):e686-7. PubMed ID: 25683228
[No Abstract] [Full Text] [Related]
[Next] [New Search]